Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jackson K Mukonzo

Showing results (1-10 of 26) with videos related to

Pageof 3
Sort By:
Computers in Biology and Medicine|April 25, 2016
Transition modeling of neuropsychiatric impairment in HIVKuteesa R Bisaso, Jackson K Mukonzo, Ene I Ette
In Silico Pharmacology|October 30, 2023
A mechanistic assessment of the nature of pharmacodynamic drug-drug interaction in vivo and in vitroKuteesa R Bisaso, Jackson K Mukonzo, Ene I Ette
Journal of Clinical Pharmacy and Therapeutics|July 13, 2021
Application of the anatomical chemical system/defined daily doses: Challenges and way forward for resource-limited countriesHanifah Nantongo, Vincent Batwaala, Victoria Nambasa, et al.
Journal of Clinical Pharmacology|May 6, 2015
Markov model for characterizing neuropsychologic impairment and Monte Carlo simulation for optimizing efavirenz therapyKuteesa R Bisaso, Jackson K Mukonzo, Ene I Ette
Pharmacology Research & Perspectives|June 16, 2026
Differential Impact of Pharmacokinetic and Pharmacodynamic Variability on Response to Combination TherapyKuteesa R Bisaso, Ronald Kadada Karyaburo, Jackson K Mukonzo, et al.
Journal of Clinical Pharmacology|February 26, 2020
Maximizing Knowledge Extraction From Patient-Reported Outcome Data Using Exposure-Outcome Item Response Modeling Approach: Understanding Efavirenz-Induced Central Nervous System ToxicityKarungi S Bisaso, Kuteesa R Bisaso, Jackson K Mukonzo, et al.
BMC Medical Informatics and Decision Making|September 6, 2018
A comparative study of logistic regression based machine learning techniques for prediction of early virological suppression in antiretroviral initiating HIV patientsKuteesa R Bisaso, Susan A Karungi, Agnes Kiragga, et al.
Therapeutic Drug Monitoring|April 2, 2010
Genetic variations in ABCB1 and CYP3A5 as well as sex influence quinine disposition among UgandansJackson K Mukonzo, Paul Waako, Jasper Ogwal-Okeng, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|October 11, 2025
Increased risk of neuropsychiatric adverse events with dolutegravir-based antiretroviral therapy during pregnancy: Findings from a prospective cohort studyHadijja Namwase, Jackson K Mukonzo, Collins Ankunda, et al.
Pharmacogenomics|October 11, 2014
CYP2B6 genotype, but not rifampicin-based anti-TB cotreatments, explains variability in long-term efavirenz plasma exposureJackson K Mukonzo, Sarah Nanzigu, Paul Waako, et al.
Pageof 3

Showing results (1-10 of 26) with videos related to

Sort By:
Pageof 3
Computers in Biology and Medicine|April 25, 2016
Transition modeling of neuropsychiatric impairment in HIVKuteesa R Bisaso, Jackson K Mukonzo, Ene I Ette
In Silico Pharmacology|October 30, 2023
A mechanistic assessment of the nature of pharmacodynamic drug-drug interaction in vivo and in vitroKuteesa R Bisaso, Jackson K Mukonzo, Ene I Ette
Journal of Clinical Pharmacy and Therapeutics|July 13, 2021
Application of the anatomical chemical system/defined daily doses: Challenges and way forward for resource-limited countriesHanifah Nantongo, Vincent Batwaala, Victoria Nambasa, et al.
Journal of Clinical Pharmacology|May 6, 2015
Markov model for characterizing neuropsychologic impairment and Monte Carlo simulation for optimizing efavirenz therapyKuteesa R Bisaso, Jackson K Mukonzo, Ene I Ette
Pharmacology Research & Perspectives|June 16, 2026
Differential Impact of Pharmacokinetic and Pharmacodynamic Variability on Response to Combination TherapyKuteesa R Bisaso, Ronald Kadada Karyaburo, Jackson K Mukonzo, et al.
Journal of Clinical Pharmacology|February 26, 2020
Maximizing Knowledge Extraction From Patient-Reported Outcome Data Using Exposure-Outcome Item Response Modeling Approach: Understanding Efavirenz-Induced Central Nervous System ToxicityKarungi S Bisaso, Kuteesa R Bisaso, Jackson K Mukonzo, et al.
BMC Medical Informatics and Decision Making|September 6, 2018
A comparative study of logistic regression based machine learning techniques for prediction of early virological suppression in antiretroviral initiating HIV patientsKuteesa R Bisaso, Susan A Karungi, Agnes Kiragga, et al.
Therapeutic Drug Monitoring|April 2, 2010
Genetic variations in ABCB1 and CYP3A5 as well as sex influence quinine disposition among UgandansJackson K Mukonzo, Paul Waako, Jasper Ogwal-Okeng, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|October 11, 2025
Increased risk of neuropsychiatric adverse events with dolutegravir-based antiretroviral therapy during pregnancy: Findings from a prospective cohort studyHadijja Namwase, Jackson K Mukonzo, Collins Ankunda, et al.
Pharmacogenomics|October 11, 2014
CYP2B6 genotype, but not rifampicin-based anti-TB cotreatments, explains variability in long-term efavirenz plasma exposureJackson K Mukonzo, Sarah Nanzigu, Paul Waako, et al.
Pageof 3